AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25284751
Drug: Korean red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean red ginseng (KRG) 500 mg, six capsules twice daily for 8 weeks
Trial: 24321164
Drug: Acetyl-L-carnitine (ALCAR)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (ALCAR) 2g
Trial: 18538054
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL 0.25% levobupivacaine
Trial: 18538054
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL saline placebo (control group)
Trial: 9562227
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (250 ml)
Trial: 7717487
Drug: Thiopentone (step
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (step 1: 1.25 mg.kg‐1 followed by 2.5 mg.kg‐1.h‐1; step 2: 1.25 mg.kg‐1 and 12.5 mg.kg‐1.h‐1; n = 15)
Trial: 7717487
Drug: Propofol (step
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (step 1: 0.5 mg.kg‐1, 1 mg.kg‐1.h‐1; step 2: 0.5 mg.kg‐1, 5 mg.kg‐1.h‐1; n = 15)
Trial: 6791864
Drug: Penicillin (55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (55 mg/kg/day for 7 days)
Trial: 24635935
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between 1000 pulse and 2000 pulse treatment arms
Trial: 23754188
Drug: Rilonacept (2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilonacept (2.2 mg/kg or 4.4 mg/kg)
Trial: 20804367
Drug: Methyl B12
RxNorm normalized name: Methyl vitamin B12
DrugBank: Mecobalamin (DB03614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyl B12 (64.5 mcg/kg every three days for 6 weeks)
Trial: 15882144
Drug: Ucn 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ucn 1 infusion (50 microg intravenously over 1 hour)
Trial: 12933408
Drug: Droperidol 5
RxNorm normalized name: droPERidol 5 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 5 micro g
Trial: 12933408
Drug: Droperidol 15
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droperidol 15 micro g
Trial: 12933408
Drug: Droperidol 50
RxNorm normalized name: fentanyl citrate/droperidol 50 mcg-2.5 mg/mL INJECTION AMPUL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 50 micro g
Trial: 30091814
Drug: Therapeutic Education
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic Education System (TES) and treatment-as-usual (control).
Trial: 30091814
Drug: Treatment-as-usual (control).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (control).
Trial: 18498916
Drug: MPA AUC(0‐12h)
RxNorm normalized name: polyurethane-34 (55 MPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA AUC(0‐12h) ranges >60 mg/L x h(‐1)
Trial: 18498916
Drug: MPA AUC(0‐12h)
RxNorm normalized name: polyurethane-34 (55 MPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA AUC(0‐12h) ranges <30 mg/L x h(‐1), 30‐60 mg/L x h(‐1), >60 mg/L x h(‐1)
Trial: 18498916
Drug: MPA AUC(0‐12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA AUC(0‐12 h) ranges <30, 30‐60, >60 mg/L x h(‐1)
Trial: 10561191
Drug: G-CSF and
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF and G-CSF + EPO
Trial: 8777066
Drug: Maintenance group
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance group received calls twice a month for six months
Trial: 1890155
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg DHSP
Trial: 9272426
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg cyproterone acetate
Trial: 3882480
Drug: Squaric acid
RxNorm normalized name: Squaric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Squaric acid dibutyl ester (SADBE) treatment on the right side of the scalp
Trial: 31718637
Drug: Antifibrotic drugs
RxNorm normalized name: Antihidrotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifibrotic drugs (10 patients treated with pirfenidone at 2403 mg/day, 1 patient with nintedanib at 300 mg/day)
Trial: 30630794
Drug: Combined medication
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined medication of abraxane and trastuzumab
Trial: 30630794
Drug: Single medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single medication of trastuzumab
Trial: 26975590
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (initiated within 24 hours after ICU admission)
Trial: 26975590
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (initiated on the morning of the 8th day in the ICU)
Trial: 23619160
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D₃ supplementation (2000 IU per day)
Trial: 16260696
Drug: High-dose tumor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tumor cell vaccine
Trial: 16260696
Drug: Low-dose tumor
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tumor cell vaccine
Trial: 9844331
Drug: Occlusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusion therapy
Trial: 29502374
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg per day for 9 weeks
Trial: 29502374
Drug: Pemetrexed combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed combined with cisplatin chemotherapy (2 cycles followed by 3-week discontinuation)
Trial: 29502374
Drug: Neoadjuvant targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant targeted therapy group
Trial: 29502374
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy group
Trial: 22490487
Drug: Resistance plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance plus loading dose group (R + L): 200 mg aspirin and 150 mg clopidogrel per day
Trial: 22490487
Drug: Resistance plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance plus routine dose group (R + R): 100 mg aspirin plus 75 mg clopidogrel per day
Trial: 20018367
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL of the pandemic vaccine (Fluval P, a monovalent vaccine with 6 microg haemagglutinin per 0.5 mL content and aluminium phosphate gel adjuvant; n=178)
Trial: 20018367
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL of the pandemic vaccine and 0.5 mL of the seasonal trivalent vaccine (Fluval AB, a trivalent inactivated whole-virion influenza vaccine; n=177)
Trial: 17373172
Drug: 5% 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-fluorouracil cream
Trial: 9533423
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (captopril up to 100 mg/day + 5 mg bendrofluazide)
Trial: 2655909
Drug: Dyazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dyazide (25 mg hydrochlorothiazide and 50 mg triamterene), one capsule daily for eight weeks
Trial: 2655909
Drug: Placebo, one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, one capsule daily for eight weeks
Trial: 18081732
Drug: DDP733 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDP733 0.5 mg
Trial: 18081732
Drug: DDP733 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDP733 0.8 mg
Trial: 18081732
Drug: DDP733 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDP733 1.4 mg
Trial: 15080819
Drug: Tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus ointment (0.1%) given twice a day
Trial: 15080819
Drug: Oral cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporine (3 mg/kg) given once daily
Trial: 24885317
Drug: Telephone counselling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone counselling intervention by pharmacist 2 or 3 weeks after a new prescription.
Trial: 17952423
Drug: Halofantrine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine (500 mg) with kolanut (12.5 g)
Trial: 17952423
Drug: Halofantrine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine (500 mg) alone
Trial: 12439119
Drug: Omeprazole triple
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole triple therapy (OAC: omeprazole 20 mg b.d., amoxicillin 1 g b.d., clarithromycin 0.5 g b.d.)
Trial: 12439119
Drug: Omeprazole quadruple
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole quadruple therapy (OBMT: omeprazole 20 mg b.d., colloidal bismuth subcitrate 120 mg q.i.d., metronidazole 0.5 g t.i.d., tetracycline hydrochloride 0.5 g q.i.d.)
Trial: 2266673
Drug: L-lactate (46
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-lactate (46 mM)
Trial: 7420419
Drug: Restricted environmental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted environmental stimulation therapy (lying on a bed in a dark, silent room) combined with self-management messages
Trial: 26393386
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day istradefylline plus sham‐rTMS
Trial: 26393386
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day istradefylline plus sham‐rTMS
Trial: 24193859
Drug: Home-based infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based infusion therapy (ERT with agalsidase alfa every two weeks)
Trial: 3301457
Drug: twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily sustained release theophylline suspension
Trial: 3301457
Drug: standard twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard twice daily slow release tablets
Trial: 29783914
Drug: Fist Assist®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fist Assist® device applied 15 cm proximal to arteriovenous fistula, enabling 60 mmHg of cyclic compression for 6 hours daily for 30 days
Trial: 27464712
Drug: Liquid emulsion
RxNorm normalized name: propofol lipid emulsion Injection [Propoven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid emulsion of coenzyme Q10 (250 mg daily for 1 week)
Trial: 27464712
Drug: Solid formulation
RxNorm normalized name: Corydalis solida whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid formulation of coenzyme Q10 (250 mg daily for 1 week)
Trial: 27464712
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (liquid emulsion and solid)
Trial: 25406242
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in carbohydrate intake (≤9.5 g/d)
Trial: 15562791
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) for more than 1 year
Trial: 8301062
Drug: Imidazole-salicylate (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidazole-salicylate (750 mg)
Trial: 3329078
Drug: Neo Sampoon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo Sampoon foaming vaginal contraceptive tablets
Trial: 28440105
Drug: Doxazosin 8
RxNorm normalized name: doxazosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 8 mg/day
Trial: 12664317
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg, 2 times daily for 12 days
Trial: 12664317
Drug: Meloxicam 7.5
RxNorm normalized name: meloxicam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 7.5 mg for 12 days
Trial: 1718699
Drug: Diltiazem and
RxNorm normalized name: Diltiazem and enalapril only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem and aspirin administration
Trial: 7103635
Drug: Fluoxymesterone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxymesterone (30 mg/day) plus necessary transfusions
Trial: 18534135
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg once a day for up to 28 days
Trial: 18534135
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg once a day for up to 28 days
Trial: 18534135
Drug: Sodium diclofenac
RxNorm normalized name: Diclofenac Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium diclofenac 50 mg twice a day for 10 days (Control)
Trial: 12450889
Drug: Caffeine treatment
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine treatment (870 mg caffeine/d)
Trial: 12450889
Drug: Coffee treatment
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee treatment (0.9 L paper-filtered coffee providing approximately 870 mg caffeine/d)
Trial: 12450889
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (3 placebo capsules)
Trial: 12450889
Drug: Coffee treatment
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee treatment (0.45 L coffee)
Trial: 9807846
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration of tenoxicam (10 mg in 10 ml normal saline)
Trial: 9807846
Drug: Intravenous tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tenoxicam (20 mg)
Trial: 9807846
Drug: Intravenous tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tenoxicam (10 mg)
Trial: 9807846
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preoperative local infiltration or intravenous tenoxicam)
Trial: 2611126
Drug: Clinitar (purified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinitar (purified coal tar cream)
Trial: 415880
Drug: NH4Cl administration
RxNorm normalized name: Ammonium Chloride
DrugBank: Ammonium chloride (DB06767)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NH4Cl administration
Trial: 31931160
Drug: Inhaled Lavandula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Lavandula angustifolia Mill. Essential oil
Trial: 30156312
Drug: Firocoxib (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firocoxib (0.3 mg/kg, i.v. loading dose; 0.1 mg/kg, i.v., q24h)
Trial: 30156312
Drug: Flunixin meglumine
RxNorm normalized name: Flunixin Meglumine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunixin meglumine (1.1 mg/kg, i.v., q12h)
Trial: 28479288
Drug: Concurrent Foley
RxNorm normalized name: CATHETER,FOLEY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Foley bulb and oxytocin
Trial: 26542513
Drug: Prasugrel pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel pretreatment (30 mg loading dose)
Trial: 22710541
Drug: 5% KOH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% KOH solution
Trial: 17264849
Drug: Topiramate 96
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate 96 mg b.i.d.
Trial: 15230906
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ibuprofen and 1000 mg acetaminophen
Trial: 9164365
Drug: Placebo acaricide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo acaricide treatment combined with avoidance measures
Trial: 1975487
Drug: Zidovudine, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine, 500 mg orally every 4 hours for 12 weeks, combined with six peripheral blood lymphocyte infusions and bone marrow transplantation
Trial: 1975487
Drug: Zidovudine, 100
RxNorm normalized name: Zidovudine, 100 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine, 100 mg every 4 hours for 12 months
Trial: 22268972
Drug: 5-weekly group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-weekly group mantram intervention
Trial: 15854171
Drug: Ipocol (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipocol (2.4 g daily for 8 weeks)
Trial: 15854171
Drug: Asacol (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asacol (2.4 g daily for 8 weeks)
Trial: 14521276
Drug: Neurofeedback (NFB)
RxNorm normalized name: NFBA
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neurofeedback (NFB) treatment applied in the region with the highest theta/alpha ratio, triggering a sound when the ratio fell below a threshold value, 20 half-hour sessions at a rate of 2 per week.
Trial: 7593419
Drug: Carbenoxolone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone (100 mg every 8 h for 7 days)
Trial: 2182032
Drug: 2-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose insulin regimen (mainly intermediate acting insulin before breakfast and dinner)
Trial: 2182032
Drug: 4-dose insulin
RxNorm normalized name: insulin, regular, human 4 UNT [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-dose insulin regimen (regular insulin preprandially with intermediate acting insulin at bedtime)
Trial: 2182032
Drug: 2-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose insulin regimen
Trial: 2182032
Drug: 4-dose insulin
RxNorm normalized name: insulin, regular, human 4 UNT [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-dose insulin regimen
Trial: 2182032
Drug: 2-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose insulin regimen and 4-dose insulin regimen
Trial: 396655
Drug: LS 519
RxNorm normalized name: Emcor LS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LS 519 (75 mg/day)
Trial: 396655
Drug: LS 519
RxNorm normalized name: Emcor LS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LS 519 (150 mg/day)
Trial: 396655
Drug: Carbenoxolone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone (300 mg/day)
Trial: 24226711
Drug: Esomeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (20 mg/d for 3 days)
Trial: 17556414
Drug: Lead-chelation therapy
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead-chelation therapy with calcium disodium EDTA
Trial: 17556414
Drug: Lead-chelation therapy
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead-chelation therapy
Trial: 17556414
Drug: Repeated chelation
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated chelation therapy
Trial: 14764176
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug therapy (mainly amiodarone)
Trial: 9337166
Drug: Subcutaneous port
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous port insertion
Trial: 8202898
Drug: Frusemide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 40 mg with flurbiprofen 200 mg
Trial: 2438319
Drug: Inosiplex (isoprinosine)
RxNorm normalized name: Inosiplex
DrugBank: Inosine pranobex (DB13156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosiplex (isoprinosine) therapy for 20 weeks
Trial: 24237190
Drug: Chromium plus
DrugBank: Vanadium (DB13971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium plus sertraline
Trial: 21168715
Drug: CNI discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNI discontinuation
Trial: 11049917
Drug: Cisatracurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.2 mg/kg IV bolus, followed by infusion
Trial: 11049917
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg IV, followed by infusion
Trial: 8831436
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of interpersonal psychotherapy and tricyclic antidepressant (nortriptyline for elderly, imipramine for midlife) during acute-phase therapy
Trial: 8831436
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment with the same therapy
Trial: 22651541
Drug: Fluticasone propionate-salmeterol
RxNorm normalized name: Fluticasone Propionate/Salmeterol Xinafoate 55 MCG/1 ACTUATION-14 MCG/1 ACTUATION Inhalation Powder [FLUTICASONE PROPIONATE-SALMETEROL XINAFOATE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate-salmeterol 250/50 mcg (FSC)
Trial: 14693626
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 2.5 mg (group B)